FIELD: medicine, pharmaceutics.
SUBSTANCE: there are offered a combination for preventing or treating a proliferative disease, containing a microtubular active agent epothilone B and a pharmaceutically active agent, 1H-pyrazolo[3,4-d]pyrimidine-4-amine 3-(4-chloriophenyl)-1-(1,1-dimethylethyl)-(9CI); the related pharmaceutical composition containing said combination, methods of preventing and treating (versions), a commercial packing including said combination (versions). Particularly, the proliferative disease can represent ovarian cancer, carcinoma of lung and melanoma.
EFFECT: what is shown is synergism of the combination in growth inhibition of non-small cell carcinoma of lung in relation to independent action of its ingredients.
17 cl, 3 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATIONS CONTAININS Bcr-Abl/c-Kit/PDGF-RTK INHIBITORS FOR TREATING CANCER | 2007 |
|
RU2452492C2 |
| COMBINATIONS OF THERAPEUTIC AGENTS APPLICABLE FOR TREATING CANCER | 2007 |
|
RU2447891C2 |
| COMBINATIONS OF HSP90 INHIBITOR | 2009 |
|
RU2519673C2 |
| TREATING NEUROENDOCRINE TUMOURS | 2006 |
|
RU2487711C2 |
| TREATING TUBEROUS SCLEROSIS | 2007 |
|
RU2473343C2 |
| COMBINATION CONTAINING IRON COMPLEX AND ANTINEOPLASTIC AGENT, AND USE THEREOF | 2007 |
|
RU2469721C2 |
| APPLICATION OF MEDICATIONS, BINDING EDG-RECEPTOR, IN TREATMENT OF CANCER DISEASE | 2008 |
|
RU2426555C2 |
| APPLICATION OF EDG-RECEPTOR BINDING AGENT IN CANCER THERAPY | 2003 |
|
RU2358717C2 |
| COMBINED THERAPY | 2015 |
|
RU2695230C2 |
| COMBINED PRODUCTS CONTAINING TYROSINE KINASE INHIBITORS AND THEIR USE | 2013 |
|
RU2660354C2 |
